A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

Inclusion Criteria:

• Age greater than or equal to 18 years at the time of signing informed consent.

• Body mass index (BMI) of greater than or equal to 24 and less than 28 kilogram persquare meter ( kg/m^2) with the presence of at least one weight related complication (treated or untreated): Type 2 diabetes (T2D), hypertension, dyslipidaemia,obstructive sleep apnoea or cardiovascular disease or BMI greater than or equal to 28 and less 30 kg/m^2, with or without weight related complications at screening.

• History of at least one self-reported unsuccessful dietary effort to lose bodyweight.

For participants with T2D at screening:

• Diagnosed with T2D greater than or equal to 180 days prior to the day of screening

Treated with either:

• Diet and exercise alone or with 1-3 marketed oral antidiabetic drugs (metformin,alpha glucosidase, Sulfonylureas (SU), glinides, sodium-glucose co-transporter 2inhibitors (SGLT2i) or glitazone as a single agent or in combination) according tolocal label.

• Treatment with oral anti-diabetic drugs should be stable (same drug(s) or activeingredient, dose, and dosing frequency) for at least 60 days before screening

• Glycated haemoglobin (HbA1c) of less than or equal to 10.0 percent (less than orequal to 86 millimoles per mol [mmol/mol]) as measured by the central laboratory atscreening.

Exclusion Criteria:

• A self-reported change in body weight greater than 5 kilograms (kg) within 90 daysbefore screening irrespective of medical records.

• Treatment with any medication for the indication of obesity within the past 90 daysbefore screening.

• Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2or medullary thyroid carcinoma.

For participants without T2D at screening:

• HbA1c greater than or equal to 6.5percent (48 mmol/mol) as measured by the laboratory.

For participants with T2D at screening:

• Renal impairment with estimated Glomerular Filtration Rate (eGFR) value of less than 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2) according toChronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation asdefined by Kidney Disease Improving Global Outcomes (KDIGO) 2012 classification bythe central laboratory at screening.

• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verifiedby a fundus examination performed within the past 90 days prior to screening or inthe period between screening and randomisation. Pharmacological pupil-dilation is arequirement unless using a digital fundus photography camera specified fornon-dilated examination.